<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">72823</article-id><article-id pub-id-type="doi">10.7554/eLife.72823</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Neurotoxin-mediated ­­potent activation of the axon degeneration regulator SARM1</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-145207"><name><surname>Loreto</surname><given-names>Andrea</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6535-6436</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-249808"><name><surname>Angeletti</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-249809"><name><surname>Gu</surname><given-names>Weixi</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1185-3557</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-249810"><name><surname>Osborne</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-249811"><name><surname>Nieuwenhuis</surname><given-names>Bart</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2065-2271</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240711"><name><surname>Gilley</surname><given-names>Jonathan</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9510-7956</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-100701"><name><surname>Arthur-Farraj</surname><given-names>Peter</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1239-9392</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-249812"><name><surname>Merlini</surname><given-names>Elisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-249813"><name><surname>Amici</surname><given-names>Adolfo</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1081-7749</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-249814"><name><surname>Luo</surname><given-names>Zhenyao</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-249815"><name><surname>Hartley-Tassell</surname><given-names>Lauren</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-151632"><name><surname>Ve</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-249816"><name><surname>Desrochers</surname><given-names>Laura M</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-249817"><name><surname>Wang</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-124359"><name><surname>Kobe</surname><given-names>Bostjan</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9413-9166</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" corresp="yes" id="author-249819"><name><surname>Orsomando</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-139686"><name><surname>Coleman</surname><given-names>Michael P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf9"/></contrib><aff id="aff1"><institution content-type="dept">Department of Clinical Neurosciences</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Department of Clinical Sciences (DISCO)</institution>, <institution>Polytechnic University of Marche</institution>, <addr-line><named-content content-type="city">Ancona</named-content></addr-line>, <country>Italy</country></aff><aff id="aff3"><institution content-type="dept">School of Chemistry and Molecular Biosciences</institution>, <institution>University of Queensland</institution>, <addr-line><named-content content-type="city">Brisbane</named-content></addr-line>, <country>Australia</country></aff><aff id="aff4"><institution content-type="dept">Institute for Glycomics</institution>, <institution>Griffith University</institution>, <addr-line><named-content content-type="city">Southport</named-content></addr-line>, <country>Australia</country></aff><aff id="aff5"><institution content-type="dept">Institute for Glycomics</institution>, <institution>Griffith University</institution>, <addr-line><named-content content-type="city">Brisbane</named-content></addr-line>, <country>Australia</country></aff><aff id="aff6"><institution content-type="dept">Neuroscience, BioPharmaceuticals R and D</institution>, <institution>AstraZeneca</institution>, <addr-line><named-content content-type="city">Waltham</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution content-type="dept">School of Chemistry and Molecular Biosciences</institution>, <institution>The University of Queensland</institution>, <addr-line><named-content content-type="city">Brisbane</named-content></addr-line>, <country>Australia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-13593"><name><surname>Chao</surname><given-names>Moses V</given-names></name><role>Reviewing editor</role><aff><institution>New York University Langone Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>al850@cam.ac.uk</email> (AL);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>g.orsomando@staff.univpm.it</email> (GO);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>mc469@cam.ac.uk</email> (MC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>06</day><month>12</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e72823</elocation-id><history><date date-type="received"><day>05</day><month>08</month><year>2021</year></date><date date-type="accepted"><day>05</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Loreto et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Loreto et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-72823-v1.pdf"/><abstract><p>Axon loss underlies symptom onset and progression in many neurodegenerative disorders. Axon degeneration in injury and disease is promoted by activation of the nicotinamide adenine dinucleotide (NAD)-consuming enzyme SARM1. Here, we report a novel activator of SARM1, a metabolite of the pesticide and neurotoxin vacor. Removal of SARM1 completely rescues mouse neurons from vacor-induced neuron and axon death <italic>in vitro</italic> and <italic>in vivo</italic>. We present the crystal structure the <italic>Drosophila</italic> SARM1 regulatory domain complexed with this activator, the vacor metabolite VMN, which as the most potent activator yet know is likely to support drug development for human SARM1 and NMNAT2 disorders. This study indicates the mechanism of neurotoxicity and pesticide action by vacor, raises important questions about other pyridines in wider use today, provides important new tools for drug discovery, and demonstrates that removing SARM1 can robustly block programmed axon death induced by toxicity as well as genetic mutation.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>210904/Z/18/Z</award-id><principal-award-recipient><name><surname>Loreto</surname><given-names>Andrea</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>206634</award-id><principal-award-recipient><name><surname>Arthur-Farraj</surname><given-names>Peter</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/S009582/1</award-id><principal-award-recipient><name><surname>Loreto</surname><given-names>Andrea</given-names></name><name><surname>Gilley</surname><given-names>Jonathan</given-names></name><name><surname>Coleman</surname><given-names>Michael P</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>UNIVPM</institution></institution-wrap></funding-source><award-id>RSA 2016-18 and 2017-19</award-id><principal-award-recipient><name><surname>Orsomando</surname><given-names>Giuseppe</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Australian National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>NHMRC 1160570</award-id><principal-award-recipient><name><surname>Kobe</surname><given-names>Bostjan</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Sight Research UK</institution></institution-wrap></funding-source><award-id>SAC 041</award-id><principal-award-recipient><name><surname>Osborne</surname><given-names>Andrew</given-names></name><name><surname>Nieuwenhuis</surname><given-names>Bart</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Weixi Gu, receives research funding from Disarm Therapeutics, a wholly-owned subsidiary of Eli Lilly and Co., Cambridge, MA, USA, but they had no role in the research presented here..</p></fn><fn fn-type="conflict" id="conf3"><p>Andrew Osborne, is affiliated with Ikarovec Ltd. The author has no financial interests to declare..</p></fn><fn fn-type="conflict" id="conf4"><p>Zhenyao Luo, receives research funding from Disarm Therapeutics, a wholly- owned subsidiary of Eli Lilly and Co., Cambridge, MA, USA, but they had no role in the research presented here..</p></fn><fn fn-type="conflict" id="conf5"><p>Thomas Ve, Thomas Ve receives research funding from Disarm Therapeutics, a wholly-owned subsidiary of Eli Lilly &amp; Co., Cambridge, MA, USA, but they had no role in the research presented here..</p></fn><fn fn-type="conflict" id="conf6"><p>Laura M Desrochers, This work is in part funded by a BBSRC/AstraZeneca Industrial Partnership Award and Laura M Desrochers was an employee of AstraZeneca for part of the project. Laura M Desrochers is affiliated with Vertex Pharmaceuticals. The author has no financial interests to declare..</p></fn><fn fn-type="conflict" id="conf7"><p>Qi Wang, This work is in part funded by a BBSRC/AstraZeneca Industrial Partnership Award and Qi Wang was an employee of AstraZeneca for part of the project. Qi Wang is affiliated with Kymera Therapeutics. The author has no financial interests to declare..</p></fn><fn fn-type="conflict" id="conf8"><p>Bostjan Kobe, receives research funding from Disarm Therapeutics, a wholly-owned subsidiary of Eli Lilly and Co., Cambridge, MA, USA, but they had no role in the research presented here..</p></fn><fn fn-type="conflict" id="conf9"><p>Michael P Coleman, holds funding jointly provided by AstraZeneca for academic research and consults for Nura Bio, but they had no role in the research presented here..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All studies conformed to the institution's ethical requirements in accordance with the 1986 Animals (Scientific Procedures) Act under Project Licences PPL P98A03BF9 and PP1824519, and in accordance with the Association for Research in Vision and Ophthalmology's Statement for the Use of Animals in Ophthalmic and Visual Research.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 1-7 and figure supplements. VMN-bound dSARM1ARM crystal structure has been deposited in the Protein Data Bank (PDB: 7M6K).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Loreto A</collab><collab>et al</collab></person-group><year iso-8601-date="2021">2021</year><source>VMN-bound dSARM1ARM crystal structure</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/unreleased/7M6K">https://www.rcsb.org/structure/unreleased/7M6K</ext-link><comment>Protein Data Bank, 7M6K</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-72823-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>